[
  {
    "ts": null,
    "headline": "Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most.",
    "summary": "Big changes could be coming to pharmaceutical advertising on TV, potentially causing problems for the broadcasters and networks that get paid to host those commercials.  TV watchers have become all too familiar with seeing prescription drug ads while watching their favorite programs.  Hearing personal stories about how  Novo Nordisk’s  Wegovy led to weight loss or that “healing is possible” with  Johnson & Johnson’s  Tremfya has become routine for viewers.",
    "url": "https://finnhub.io/api/news?id=ef031a64d1e0048d78b962fb09dfc743fa82b51b16d70e2c3d958543cd04d7e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757626800,
      "headline": "Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most.",
      "id": 136703824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Big changes could be coming to pharmaceutical advertising on TV, potentially causing problems for the broadcasters and networks that get paid to host those commercials.  TV watchers have become all too familiar with seeing prescription drug ads while watching their favorite programs.  Hearing personal stories about how  Novo Nordisk’s  Wegovy led to weight loss or that “healing is possible” with  Johnson & Johnson’s  Tremfya has become routine for viewers.",
      "url": "https://finnhub.io/api/news?id=ef031a64d1e0048d78b962fb09dfc743fa82b51b16d70e2c3d958543cd04d7e3"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Thursday: Warner Bros., Paramount, Opendoor, Alibaba",
    "summary": "↗️ Warner Bros. Discovery (WBD): Shares of the entertainment company surged over one-third after The Wall Street Journal reported that Paramount Skydance (PSKY) is preparing a bid for the company. Paramount stock added 8%.",
    "url": "https://finnhub.io/api/news?id=d7a50e6c71c737b970c5ecd9fe1ea10b69a09df0fa712338a5c1dffb37f0c3b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757617819,
      "headline": "Stocks to Watch Thursday: Warner Bros., Paramount, Opendoor, Alibaba",
      "id": 136703860,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "↗️ Warner Bros. Discovery (WBD): Shares of the entertainment company surged over one-third after The Wall Street Journal reported that Paramount Skydance (PSKY) is preparing a bid for the company. Paramount stock added 8%.",
      "url": "https://finnhub.io/api/news?id=d7a50e6c71c737b970c5ecd9fe1ea10b69a09df0fa712338a5c1dffb37f0c3b4"
    }
  },
  {
    "ts": null,
    "headline": "Warren Buffett wouldn’t worry about cash if he retired with just $1M — here’s why and how to copy his strategy",
    "summary": "Here's how you could copy the Oracle of Omaha in today's market.",
    "url": "https://finnhub.io/api/news?id=095d10f7cb6df7f5f226156f606f2be2d05e5929b36881079bec4fc69345824f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757615400,
      "headline": "Warren Buffett wouldn’t worry about cash if he retired with just $1M — here’s why and how to copy his strategy",
      "id": 136703799,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Here's how you could copy the Oracle of Omaha in today's market.",
      "url": "https://finnhub.io/api/news?id=095d10f7cb6df7f5f226156f606f2be2d05e5929b36881079bec4fc69345824f"
    }
  },
  {
    "ts": null,
    "headline": "SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag",
    "summary": "Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.",
    "url": "https://finnhub.io/api/news?id=1fad6112ad59463d18bd223944f8602db1c6c7be4b17535a8687639c9efdf87a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757612700,
      "headline": "SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag",
      "id": 136703862,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.",
      "url": "https://finnhub.io/api/news?id=1fad6112ad59463d18bd223944f8602db1c6c7be4b17535a8687639c9efdf87a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie shares hit record high as key immunology drug set for exclusivity until 2037",
    "summary": "(Reuters) -AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, according to some analysts.  Rinvoq, used for the treatment of rheumatoid arthritis and other autoimmune diseases, is AbbVie's second best-selling drug behind Skyrizi.  J.P. Morgan analyst Chris Schott said the extension gives AbbVie \"several more years of runway on one of its key growth drivers\", providing more time to develop its experimental drugs ahead of major loss of exclusivity in the mid-2030s.",
    "url": "https://finnhub.io/api/news?id=144f6f6ead064fe71109e7af0b5d186c26ec25893415599a808ade6984fc80c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757611488,
      "headline": "AbbVie shares hit record high as key immunology drug set for exclusivity until 2037",
      "id": 136703863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "(Reuters) -AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, according to some analysts.  Rinvoq, used for the treatment of rheumatoid arthritis and other autoimmune diseases, is AbbVie's second best-selling drug behind Skyrizi.  J.P. Morgan analyst Chris Schott said the extension gives AbbVie \"several more years of runway on one of its key growth drivers\", providing more time to develop its experimental drugs ahead of major loss of exclusivity in the mid-2030s.",
      "url": "https://finnhub.io/api/news?id=144f6f6ead064fe71109e7af0b5d186c26ec25893415599a808ade6984fc80c8"
    }
  },
  {
    "ts": null,
    "headline": "Why AbbVie Stock Is Jumping Today",
    "summary": "AbbVie's growth prospects are now more secure thanks to its latest news.",
    "url": "https://finnhub.io/api/news?id=968effae8f8b35bc33fe3cf48d2e322158cfd7b2cd8d9e13f02ba36d7af1e397",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757609424,
      "headline": "Why AbbVie Stock Is Jumping Today",
      "id": 136703866,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie's growth prospects are now more secure thanks to its latest news.",
      "url": "https://finnhub.io/api/news?id=968effae8f8b35bc33fe3cf48d2e322158cfd7b2cd8d9e13f02ba36d7af1e397"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=74887358059377a0d05cf75e78969bd3b1c4c85ad6902a3966274cb2e8b6c2a8",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757608260,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 136751571,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=74887358059377a0d05cf75e78969bd3b1c4c85ad6902a3966274cb2e8b6c2a8"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie in Settlement With Generic Drugmakers on Rinvoq",
    "summary": "The biopharmaceutical company doesn’t expect U.S. generic entry for the drug before 2037 now that it has settled litigation.",
    "url": "https://finnhub.io/api/news?id=0c4612cf73e151756328f225138048025c8e3a1184102eb0d9f618f367dcba78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757607420,
      "headline": "AbbVie in Settlement With Generic Drugmakers on Rinvoq",
      "id": 136701655,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The biopharmaceutical company doesn’t expect U.S. generic entry for the drug before 2037 now that it has settled litigation.",
      "url": "https://finnhub.io/api/news?id=0c4612cf73e151756328f225138048025c8e3a1184102eb0d9f618f367dcba78"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Breaks Out As Its Cash Cow Lives To Fight Another Day",
    "summary": "AbbVie Stock Breaks Out As Its Cash Cow Lives To Fight Another Day",
    "url": "https://finnhub.io/api/news?id=69dc2f1a0b50ac4d415d13feeee4153241c8bc582fac47c492b01fa028b81823",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757606801,
      "headline": "AbbVie Stock Breaks Out As Its Cash Cow Lives To Fight Another Day",
      "id": 136713232,
      "image": "",
      "related": "ABBV",
      "source": "DowJones",
      "summary": "AbbVie Stock Breaks Out As Its Cash Cow Lives To Fight Another Day",
      "url": "https://finnhub.io/api/news?id=69dc2f1a0b50ac4d415d13feeee4153241c8bc582fac47c492b01fa028b81823"
    }
  },
  {
    "ts": null,
    "headline": "Why AbbVie (ABBV) Stock Is Trading Up Today",
    "summary": "Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 4.4% in the morning session after the company announced it settled litigation with generic drug manufacturers to extend patent protection for its blockbuster autoimmune drug, RINVOQ. The agreement prevents generic competition for the drug in the U.S. until at least April 2037, a significant victory for the company. This extension provides about five more years of market exclusivity than some analysts had previously expected. RINVOQ is a",
    "url": "https://finnhub.io/api/news?id=2b441a922497197ba9fafda1d42bd9395745c94ca0f05a6cde05916ee2ccfd2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757606190,
      "headline": "Why AbbVie (ABBV) Stock Is Trading Up Today",
      "id": 136701656,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 4.4% in the morning session after the company announced it settled litigation with generic drug manufacturers to extend patent protection for its blockbuster autoimmune drug, RINVOQ. The agreement prevents generic competition for the drug in the U.S. until at least April 2037, a significant victory for the company. This extension provides about five more years of market exclusivity than some analysts had previously expected. RINVOQ is a",
      "url": "https://finnhub.io/api/news?id=2b441a922497197ba9fafda1d42bd9395745c94ca0f05a6cde05916ee2ccfd2c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie stock rises after securing patent protection for RINVOQ until 2037",
    "summary": "Investing.com -- AbbVie (NYSE:ABBV) stock rose over 3% after the company announced it has settled litigation with all generic manufacturers that filed applications for generic versions of its RINVOQ medication, securing patent protection until 2037.",
    "url": "https://finnhub.io/api/news?id=115d1b6e773c1368d2326a8065c18369098d960359f8f6684677add6140ef67d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757600827,
      "headline": "AbbVie stock rises after securing patent protection for RINVOQ until 2037",
      "id": 136701658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com -- AbbVie (NYSE:ABBV) stock rose over 3% after the company announced it has settled litigation with all generic manufacturers that filed applications for generic versions of its RINVOQ medication, securing patent protection until 2037.",
      "url": "https://finnhub.io/api/news?id=115d1b6e773c1368d2326a8065c18369098d960359f8f6684677add6140ef67d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=5814ca3f88a401a42dbb1e272b01cfdbee38cbdd879cd231d84ff13f773dc07e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757595605,
      "headline": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 136701659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=5814ca3f88a401a42dbb1e272b01cfdbee38cbdd879cd231d84ff13f773dc07e"
    }
  }
]